Inventor · disambiguated record
Michael Baltezor
Also filed as: BALTEZOR MICHAEL · BALTEZOR MICHAEL J
25 granted patents·27 pending applications·540 citations·filing 1993–2025
96Inventor score
Files withCRITITECH INC44CARDERM CAPITAL L P3CAREFUSION 2200 INC2POGANY STEFANO A1THE US SECRETARY DEPARTMENT OF HEALTH AND HUMAN SERVIC1
Top patents by PatentIndex Score
52 records- 0197US9814685B2Taxane particles and their useCRITITECH INC·Filed 2016·Granted Nov 14, 2017·40 cites·18 claims
- 0296US10729673B2Taxane particles and their useCRITITECH INC·Filed 2020·Granted Aug 4, 2020·11 cites·22 claims
- 0396US9918957B2Methods for making compound particlesCRITITECH INC·Filed 2017·Granted Mar 20, 2018·23 cites·18 claims
- 0495US10507195B2Taxane particles and their useCRITITECH INC·Filed 2018·Granted Dec 17, 2019·18 cites·28 claims
- 0594US10507181B2Methods for treating lung disordersCRITITECH INC·Filed 2019·Granted Dec 17, 2019·10 cites·23 claims
- 0694US10398646B2Methods for treating lung disordersCRITITECH INC·Filed 2018·Granted Sep 3, 2019·10 cites·20 claims
- 0794US5286497ADiltiazem formulationCARDERM CAPITAL L P·Filed 1993·Granted Feb 15, 1994·230 cites·13 claims
- 0891US11123322B2Taxane particles and their useCRITITECH INC·Filed 2019·Granted Sep 21, 2021·2 cites·18 claims
- 0991US5439689ADiltiazem formulationCARDERM CAPITAL L P·Filed 1993·Granted Aug 8, 1995·122 cites·22 claims
- 1090US2025186390A1Taxane Particles and Their UseCRITITECH INC·Filed 2024·Application pending·0 cites
- 1186US12329858B2Local delivery of antineoplastic particles in combination with systemic delivery of immunotherapeutic agents for the treatment of cancerCRITITECH INC·Filed 2024·Granted Jun 17, 2025·0 cites·19 claims
- 1286US10993927B2Taxane particles and their useCRITITECH INC·Filed 2020·Granted May 4, 2021·1 cites·18 claims
- 1385US5470584ADiltiazem formulationCARDERM CAPITAL L P·Filed 1995·Granted Nov 28, 1995·72 cites·9 claims
- 1484US11058639B2Local delivery of antineoplastic particles in combination with systemic delivery of immunotherapeutic agents for the treatment of cancerCRITITECH INC·Filed 2020·Granted Jul 13, 2021·1 cites·24 claims
- 1583US12128131B2Treatment of epithelial cysts by intracystic injection of antineoplastic particlesCRITITECH INC·Filed 2023·Granted Oct 29, 2024·0 cites·18 claims
- 1680US11918691B2Local delivery of antineoplastic particles in combination with systemic delivery of immunotherapeutic agents for the treatment of cancerCRITITECH INC·Filed 2023·Granted Mar 5, 2024·0 cites·14 claims
- 1780US11737972B2Treatment of epithelial cysts by intracystic injection of antineoplastic particlesCRITITECH INC·Filed 2022·Granted Aug 29, 2023·0 cites·18 claims
- 1879US2021393569A1Taxane Particles and Their UseCRITITECH INC·Filed 2021·Application pending·0 cites
- 1977US2024316056A1Formulations and methods for the prevention and treatment of tumor metastasis and tumorigenesisUS HEALTH·Filed 2024·Application pending·0 cites
- 2075US11160754B2Methods for treating lung disordersCRITITECH INC·Filed 2019·Granted Nov 2, 2021·0 cites·25 claims
- 2174US11583499B2Local delivery of antineoplastic particles in combination with systemic delivery of immunotherapeutic agents for the treatment of cancerCRITITECH INC·Filed 2021·Granted Feb 21, 2023·0 cites·21 claims
- 2274US2024226116A1Glucocorticoid Particles and Their UseCRITITECH INC·Filed 2024·Application pending·0 cites
- 2374US2020405684A1Taxane Particles and Their UseCRITITECH INC·Filed 2020·Application pending·0 cites
- 2473US12029818B2Lapatinib particles and uses thereofCRITITECH INC·Filed 2022·Granted Jul 9, 2024·0 cites·17 claims
- 2573US11523983B2Treatment of epithelial cysts by intracystic injection of antineoplastic particlesCRITITECH INC·Filed 2021·Granted Dec 13, 2022·0 cites·18 claims
- 2670US2019254957A1Treatment of Epithelial Cysts by Intracystic Injection of Antineoplastic ParticlesCRITITECH INC·Filed 2019·Application pending·0 cites
- 2770US2022096423A1Treatment of Bladder Cancer by Local Administration of Taxane ParticlesCRITITECH INC·Filed 2021·Application pending·0 cites
- 2870US2025360166A1Cisplatin particles and uses thereofCRITITECH INC·Filed 2025·Application pending·0 cites
- 2968US11738014B2Niraparib particles and uses thereofCRITITECH INC·Filed 2022·Granted Aug 29, 2023·0 cites·17 claims
- 3068US11738029B2Rucaparib particles and uses thereofCRITITECH INC·Filed 2022·Granted Aug 29, 2023·0 cites·17 claims
- 3167US11931368B2Glucocorticoid “nintedanib” particles and their useCRITITECH INC·Filed 2018·Granted Mar 19, 2024·0 cites·8 claims
- 3267US2019209515A1Treatment of Bladder Cancer by Intratumoral Injection of Taxane ParticlesCRITITECH INC·Filed 2019·Application pending·0 cites
- 3367US2019209514A1Treatment of Bladder Cancer by Local Administration of Taxane ParticlesCRITITECH INC·Filed 2019·Application pending·0 cites
- 3466US11104663B2Ciprofloxacin polymorph and its useCRITITECH INC·Filed 2018·Granted Aug 31, 2021·0 cites·19 claims
- 3565US2024216424A1Cisplatin particles and uses thereofCRITITECH INC·Filed 2022·Application pending·0 cites
- 3663US2016374953A1Methods for Making Compound ParticlesCRITITECH INC·Filed 2016·Application pending·0 cites
- 3763US2021387961A1Ciprofloxacin polymorph and its useCRITITECH INC·Filed 2021·Application pending·0 cites
- 3862US2024156861A1Cisplatin particles and uses thereofCRITITECH INC·Filed 2023·Application pending·0 cites
- 3962US2023364021A1Sorafenib particles and uses thereofCRITITECH INC·Filed 2023·Application pending·0 cites
- 4061US2022023215A1Lapatinib particles and uses thereofCRITITECH INC·Filed 2021·Application pending·0 cites
- 4161US2021214683A1Methods for isolating tumor-specific immune cells from a subject for adoptive cell therapy and cancer vaccinesCRITITECH INC·Filed 2019·Application pending·0 cites
- 4259US2021186972A1Formulations and methods for the prevention and treatment of tumor metastasis and tumorigenesisTHE US SECRETARY DEPARTMENT OF HEALTH AND HUMAN SERVIC·Filed 2019·Application pending·0 cites
- 4356US2015342872A1Use of Paclitaxel ParticlesCRITITECH INC·Filed 2014·Application pending·0 cites
- 4454US2023414510A1Niclosamide particles and uses thereofCRITITECH INC·Filed 2021·Application pending·0 cites
- 4552US2022241257A1Sorafenib particles and uses thereofCRITITECH INC·Filed 2021·Application pending·0 cites
- 4651US2019365700A1Methods for Isolating Tumor-Specific Immune Cells from a Subject for Adoptive Cell Therapy and Cancer VaccinesCRITITECH INC·Filed 2019·Application pending·0 cites
- 4745US2014235727A1Antimicrobial hydrogel polymersCAREFUSION 2200 INC·Filed 2013·Application pending·0 cites
- 4844US2018353630A1System and Methods for Tissue SterilizationCRITITECH INC·Filed 2016·Application pending·0 cites
- 4944US2013150330A1Decoquinate prodrugsPOGANY STEFANO A·Filed 2012·Application pending·0 cites
- 5044US2019365699A1Treatment of Kidney Tumors by Intratumoral Injection of Taxane ParticlesCRITITECH INC·Filed 2019·Application pending·0 cites
Showing the top 50 of 52 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Michael Baltezor files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →